355 related articles for article (PubMed ID: 9684808)
21. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin.
Callas DD; Hoppensteadt D; Fareed J
Semin Thromb Hemost; 1995; 21(2):177-83. PubMed ID: 7660140
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of platelet deposition by combined hirulog and aspirin in a rat carotid endarterectomy model.
Hamelink JK; Tang DB; Barr CF; Jackson MR; Reid TJ; Gomez ER; Alving BM
J Vasc Surg; 1995 Mar; 21(3):492-8. PubMed ID: 7877232
[TBL] [Abstract][Full Text] [Related]
23. Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor.
Cirillo R; Lippi A; Subissi A; Agnelli G; Criscuoli M
Thromb Haemost; 1996 Sep; 76(3):384-92. PubMed ID: 8883275
[TBL] [Abstract][Full Text] [Related]
24. Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial.
Fuchs J; Cannon CP
Circulation; 1995 Aug; 92(4):727-33. PubMed ID: 7641350
[TBL] [Abstract][Full Text] [Related]
25. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans.
Fox I; Dawson A; Loynds P; Eisner J; Findlen K; Levin E; Hanson D; Mant T; Wagner J; Maraganore J
Thromb Haemost; 1993 Feb; 69(2):157-63. PubMed ID: 8456428
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis.
Mirshahi M; Soria J; Soria C; Faivre R; Lu H; Courtney M; Roitsch C; Tripier D; Caen JP
Blood; 1989 Aug; 74(3):1025-30. PubMed ID: 2502207
[TBL] [Abstract][Full Text] [Related]
27. Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis.
McClanahan TB; Ignasiak DP; Juneau P; Finkle C; Winocour PD; Gallagher KP
J Thromb Thrombolysis; 1999 Jun; 7(3):301-6. PubMed ID: 10375391
[TBL] [Abstract][Full Text] [Related]
28. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty.
Topol EJ; Bonan R; Jewitt D; Sigwart U; Kakkar VV; Rothman M; de Bono D; Ferguson J; Willerson JT; Strony J
Circulation; 1993 May; 87(5):1622-9. PubMed ID: 8491018
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog.
Chamberlin JR; Lewis B; Leya F; Wallis D; Messmore H; Hoppensteadt D; Walenga JM; Moran S; Fareed J; McKiernan T
Can J Cardiol; 1995 Jun; 11(6):511-4. PubMed ID: 7780873
[TBL] [Abstract][Full Text] [Related]
30. Hirulog-like peptide reduces balloon catheter injury induced neointima formation in rat carotid artery without increase in bleeding tendency.
Xue M; Ren S; Welch S; Shen GX
J Vasc Res; 2001; 38(2):144-52. PubMed ID: 11316950
[TBL] [Abstract][Full Text] [Related]
31. Leeches to hirulogs and other thrombin-directed antithrombotics.
Fenton JW
Hematol Oncol Clin North Am; 1992 Oct; 6(5):1121-9. PubMed ID: 1400076
[TBL] [Abstract][Full Text] [Related]
32. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial.
Antman EM
Circulation; 1996 Sep; 94(5):911-21. PubMed ID: 8790025
[TBL] [Abstract][Full Text] [Related]
33. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
[TBL] [Abstract][Full Text] [Related]
34. Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction.
French JK; Edmond JJ; Gao W; White HD; Eikelboom JW
Am J Cardiovasc Drugs; 2004; 4(2):107-15. PubMed ID: 15049722
[TBL] [Abstract][Full Text] [Related]
35. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
Rao AK; Sun L; Chesebro JH; Fuster V; Harrington RA; Schwartz D; Gallo P; Matos D; Topol EJ
Circulation; 1996 Nov; 94(10):2389-95. PubMed ID: 8921778
[TBL] [Abstract][Full Text] [Related]
36. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
Direct Thrombin Inhibitor Trialists' Collaborative Group
Lancet; 2002 Jan; 359(9303):294-302. PubMed ID: 11830196
[TBL] [Abstract][Full Text] [Related]
37. Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects.
Lidón RM; Théroux P; Juneau M; Adelman B; Maraganore J
Circulation; 1993 Oct; 88(4 Pt 1):1495-501. PubMed ID: 8403297
[TBL] [Abstract][Full Text] [Related]
38. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin.
Bates SM; Weitz JI
Am J Cardiol; 1998 Oct; 82(8B):12P-18P. PubMed ID: 9809887
[TBL] [Abstract][Full Text] [Related]
39. Frequency of "optimal anticoagulation" for acute myocardial infarction after thrombolysis with front-loaded recombinant tissue-type plasminogen activator and conjunctive therapy with recombinant hirudin (HBW 023). ALKK Study Group.
Zeymer U; von Essen R; Tebbe U; Niederer W; Mäurer W; Vogt A; Neuhaus KL
Am J Cardiol; 1995 Nov; 76(14):997-1001. PubMed ID: 7484879
[TBL] [Abstract][Full Text] [Related]
40. Antithrombotic effects of hirulog in a rat carotid endarterectomy model.
Jackson MR; Reid TJ; Tang DB; O'Donnell SD; Gomez ER; Alving BM
J Surg Res; 1996 Jan; 60(1):15-22. PubMed ID: 8592407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
